Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2010

View Archived Issues

Aeolus invited to submit full proposal to BARDA for further development AEOL-10150

Premier Research begins phase II trial of Vantia's VA-111913 for menstrual cramps

Biogen Idec submits MAA in Europe and NDA in Canada for Fampridine-PR

Cytheris initiates phase IIa INSPIRE 2 trial of CYT107 in HIV-infected patients

Infinity outlines key objectives for 2010

Life Technologies to acquire AcroMetrix

Synexus finalizes its acquisition of ClinPharm

FDA approves Diagnostic Hybrids' D3 FastPoint L-DFA RSV/MPV identification kit

Celera grants UCSF license to develop test for KIF6 gene variant

Quest Diagnostics launches molecular blood test for detection of colorectal cancer

SciClone and Sigma-Tau report initial results from clinical study of Zadaxin and Focetria

FDA grants orphan drug status to Allon Therapeutics' neuroprotective drug davunetide for PSP

Laromustine/cytarabine activity in relapsed acute myeloid leukemia to be studied further

Phase IIa MLN-3897 trial suggests CCR-1 antagonism is ineffective to treat RA

NVP-BEZ235 may enhance activity of cytotoxic agents in sarcoma

Ixabepilone not active in childhood solid tumors

Transdermal patch effectively delivers teriparatide in postmenopausal women with osteoporosis

Evotec and CHDI Foundation extend collaboration to fight Huntington's disease

AstraZenenca and CrystalGenomics form collaboration to develop antibacterial agents

Genentech describes novel checkpoint kinase inhibitors as oncolytics

Novel janus kinase inhibitors disclosed by AstraZeneca

Bionomics describes potassium channel blockers for inflammatory and autoimmune diseases

NicOx presents novel antagonists of angiotensin AT2 receptor as antihypertensive agents

Sumavel DosePro launched in the U.S. for acute migraine and cluster headaches

GlaxoSmithKline presents PI3Kdelta inhibitors for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...